Comparison tool
Linaclotide vs Gonadorelin side-by-side
Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.
Comparison tool
Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.
Selected (2/4)
Share this peptide comparison
| Property | Linaclotide | Gonadorelin |
|---|---|---|
| Category | Other | Hormonal |
| Also known as | Linzess, Constella | GnRH, LHRH, Factrel |
| FDA approved | Yes | Yes |
| Clinical status | FDA approved for adult IBS-C and chronic idiopathic constipation; source also reports pediatric IBS-C ages 7+ and functional constipation ages 2+.
| Previously FDA approved as Factrel for diagnostic use; that brand is discontinued, no FDA-approved gonadorelin product is currently marketed in the US, and the source reports availability only as 503A-compounded.
|
| What to expect | IBS-C, chronic constipation, gut motility | Hormone stimulation, fertility, TRT support |
| How it works | Linaclotide is reported to bind guanylate cyclase-C on the luminal side of intestinal epithelial cells. Activation of this receptor increases cyclic GMP, which supports chloride and bicarbonate secretion into the gut and reduces sodium reabsorption. The resulting fluid shift can soften stool and accelerate intestinal transit. The source also describes a local, cyclic-GMP-linked effect on gut pain signaling, with minimal absorption into systemic circulation. | Gonadorelin is described as a synthetic GnRH peptide that engages GnRH receptors on gonadotroph cells in the anterior pituitary. The source reports signaling through phospholipase C with calcium and protein kinase C involvement, leading to LH and FSH production and release. Those gonadotropins then influence ovarian or testicular function, including sex-steroid production and gamete development. The source emphasizes pattern of exposure: pulsatile delivery, similar to endogenous GnRH rhythms of about 60 to 120 minutes, supports stimulation, whereas continuous exposure can desensitize and downregulate the receptor and reduce LH and FSH output. |
| Typical dosing | Limited community data available · See research protocols | 100-500 mcg 2-3x weekly · 2-3x weekly · IV, subcutaneous, or pulsatile pump |
| Research dosing | 290 mcg daily (IBS-C) · Once daily · Long-term / chronic use · Oral capsule on empty stomach | 100 mcg IV/SC for diagnostic testing · Single dose (diagnostic) or ongoing (therapeutic) · IV, subcutaneous, or pulsatile pump |
| Typical duration | Long-term / chronic use | Single dose (diagnostic) or ongoing (therapeutic) |
| Administration | Oral capsule on empty stomach | IV, subcutaneous, or pulsatile pump |
| Timing | Morning or as directed Take once daily on an empty stomach, at least 30 minutes before a meal, at approximately the same time each day. | Morning or as clinically directed With or without food |
| Evidence level | FDA Approved | FDA Approved |
| Possible side effects |
+2 more
|
+4 more
|
| Research summary | The source summarizes linaclotide as having regulatory-grade clinical evidence. It reports two large randomized, double-blind, placebo-controlled phase 3 IBS-C trials of roughly 800 participants each, lasting 12 and 26 weeks, where 290 mcg once daily outperformed placebo on FDA co-primary endpoints combining abdominal pain reduction with complete spontaneous bowel movements. It also reports chronic idiopathic constipation research over 12 weeks using lower doses such as 72 mcg. Serious adverse events were described as uncommon and not clearly higher than placebo, while diarrhea was the main tolerability issue and a frequent reason for discontinuation. | The source frames gonadorelin as an established GnRH molecule rather than an experimental novelty. Diagnostic GnRH stimulation testing is described as established, and pulsatile pump administration is reported in hypogonadotropic hypogonadism, delayed puberty, and fertility induction. Because the peptide is short-lived, the source notes that historical clinical use depended on pumps or frequent administration, while longer-acting GnRH agonists later displaced some uses. The source also describes off-label TRT-adjunct use as common in some clinic and online settings, but supported mainly by mechanism, small-scale experience, or anecdote rather than large randomized comparisons showing superiority over HCG. |
| References | ||
| Full profile | View Details | View Details |
Save this comparison
Keep this research set handy with a free PeptiGuide account.
Save this comparison - free accountTrack your peptide journey
Turn research into a private protocol log when you are ready.
Track your peptide journeyEducational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.